Mevacor “Pharmacy Care” Tactic Insufficient To Ensure Compliance – Panel
This article was originally published in The Tan Sheet
Executive Summary
The American Pharmacists Association's proposed "pharmacy care" model fell short of convincing FDA advisory panelists to recommend OTC status for Mevacor Daily
You may also be interested in...
Mevacor OTC Panel Rejection Elicits Third Drug Class Talk
A joint FDA panel decision to recommend against approval of over-the-counter Mevacor Daily was tempered by the endorsement of a behind-the-counter drug class by a number of panelists
Mevacor OTC Study Shows Cholesterol-Lowering Consistent With Rx Statins
A cholesterol self-management program for OTC Mevacor was effective in deterring consumers from improperly purchasing the nonprescription version of the cholesterol-lowering drug, results from the CUSTOM actual-use study show
“Pharmacy Care” OTC Category Considered By APhA Task Force
A new category of "pharmacy care" drugs could broaden access to certain over-the-counter drugs, according to the American Pharmacists Association